Skip to main content
. 2022 Apr 6;38(4):279–287. doi: 10.1089/aid.2021.0115

Table 3.

Percent of Study Participants Within Specified Adherence Ranges in the Oral Emtricitabine/Tenofovir Disoproxil Fumarate Period Based on Pharmacologic Benchmarks

Drug-period 7 doses per week 4 doses per week <4 doses per week
TFV mid 88.6% 7.6% 3.8%
TFV end 82.8% 9.7% 7.5%
FTC mid 90.8% 5.4% 3.8%
FTC end 82.8% 10.7% 6.5%